ITK and hereditary clear cell renal cell carcinoma: Pazopanib (DB06589), Fostamatinib (DB12010), and Zanubrutinib (DB15035) are inhibitors of ITK. Pazopanib is indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma in patients with prior chemotherapy.